S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:ALNY

Alnylam Pharmaceuticals Stock Forecast, Price & News

$188.53
-0.27 (-0.14%)
(As of 11/26/2021 04:00 PM ET)
Add
Compare
Today's Range
$185.65
$192.98
50-Day Range
$159.56
$209.29
52-Week Range
$121.97
$212.00
Volume
341,317 shs
Average Volume
635,464 shs
Market Capitalization
$22.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.97
30 days | 90 days | 365 days | Advanced Chart
Receive ALNY News and Ratings via Email

Sign-up to receive the latest news and ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Alnylam Pharmaceuticals logo

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Headlines

Alnylam getting a rare kind of leader
November 28, 2021 |  msn.com
Expert Ratings For Alnylam Pharmaceuticals
November 22, 2021 |  markets.businessinsider.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares Gap Up to $172.73
November 18, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ALNY
CUSIP
02043Q10
Employees
1,453
Year Founded
2002

Sales & Book Value

Annual Sales
$492.85 million
Book Value
$6.32 per share

Profitability

Net Income
$-858.28 million
Net Margins
-111.82%
Pretax Margin
-111.49%

Debt

Price-To-Earnings

Miscellaneous

Free Float
116,850,000
Market Cap
$22.55 billion
Optionable
Optionable

Company Calendar

Last Earnings
10/27/2021
Today
11/28/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/10/2022

Social Links


MarketRank

Overall MarketRank

2.09 out of 5 stars

Medical Sector

490th out of 1,391 stocks

Pharmaceutical Preparations Industry

228th out of 669 stocks

Analyst Opinion: 2.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -












Alnylam Pharmaceuticals (NASDAQ:ALNY) Frequently Asked Questions

Is Alnylam Pharmaceuticals a buy right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alnylam Pharmaceuticals stock.
View analyst ratings for Alnylam Pharmaceuticals
or view top-rated stocks.

How has Alnylam Pharmaceuticals' stock been impacted by Coronavirus?

Alnylam Pharmaceuticals' stock was trading at $101.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALNY stock has increased by 85.0% and is now trading at $188.53.
View which stocks have been most impacted by COVID-19
.

When is Alnylam Pharmaceuticals' next earnings date?

Alnylam Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Alnylam Pharmaceuticals
.

How were Alnylam Pharmaceuticals' earnings last quarter?

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) posted its quarterly earnings data on Wednesday, October, 27th. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing analysts' consensus estimates of ($1.51) by $0.21. The biopharmaceutical company had revenue of $187.63 million for the quarter, compared to the consensus estimate of $218.69 million. Alnylam Pharmaceuticals had a negative net margin of 111.82% and a negative trailing twelve-month return on equity of 94.37%. The firm's revenue for the quarter was up 49.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.18) EPS.
View Alnylam Pharmaceuticals' earnings history
.

What guidance has Alnylam Pharmaceuticals issued on next quarter's earnings?

Alnylam Pharmaceuticals issued an update on its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $790 million-$865 million, compared to the consensus revenue estimate of $853.11 million.

What price target have analysts set for ALNY?

16 Wall Street analysts have issued twelve-month price objectives for Alnylam Pharmaceuticals' shares. Their forecasts range from $47.00 to $275.00. On average, they expect Alnylam Pharmaceuticals' share price to reach $198.13 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price.
View analysts' price targets for Alnylam Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Alnylam Pharmaceuticals' key executives?

Alnylam Pharmaceuticals' management team includes the following people:

What is John M. Maraganore's approval rating as Alnylam Pharmaceuticals' CEO?

65 employees have rated Alnylam Pharmaceuticals CEO John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among Alnylam Pharmaceuticals' employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Alnylam Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

What is Alnylam Pharmaceuticals' stock symbol?

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Who are Alnylam Pharmaceuticals' major shareholders?

Alnylam Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (8.76%), BlackRock Inc. (7.46%), Wellington Management Group LLP (6.16%), Morgan Stanley (1.57%), The Manufacturers Life Insurance Company (1.45%) and Geode Capital Management LLC (1.22%). Company insiders that own Alnylam Pharmaceuticals stock include Akshay Vaishnaw, Barry E Greene, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Steven M Paul and Yvonne Greenstreet.
View institutional ownership trends for Alnylam Pharmaceuticals
.

Which major investors are selling Alnylam Pharmaceuticals stock?

ALNY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Maverick Capital Ltd., Caption Management LLC, Bellevue Group AG, Farallon Capital Management LLC, Rockefeller Capital Management L.P., International Biotechnology Trust PLC, and Bridger Management LLC. Company insiders that have sold Alnylam Pharmaceuticals company stock in the last year include Akshay Vaishnaw, Jeffrey W Dunn, John Maraganore, Laurie Keating, Steven M Paul, and Yvonne Greenstreet.
View insider buying and selling activity for Alnylam Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Alnylam Pharmaceuticals stock?

ALNY stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, BlackRock Inc., Polar Capital Holdings Plc, Baillie Gifford & Co., Franklin Resources Inc., Natixis, Jane Street Group LLC, and BNP Paribas Arbitrage SA.
View insider buying and selling activity for Alnylam Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Alnylam Pharmaceuticals?

Shares of ALNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alnylam Pharmaceuticals' stock price today?

One share of ALNY stock can currently be purchased for approximately $188.53.

How much money does Alnylam Pharmaceuticals make?

Alnylam Pharmaceuticals has a market capitalization of $22.55 billion and generates $492.85 million in revenue each year. The biopharmaceutical company earns $-858.28 million in net income (profit) each year or ($7.13) on an earnings per share basis.

How many employees does Alnylam Pharmaceuticals have?

Alnylam Pharmaceuticals employs 1,453 workers across the globe.

When was Alnylam Pharmaceuticals founded?

Alnylam Pharmaceuticals was founded in 2002.

What is Alnylam Pharmaceuticals' official website?

The official website for Alnylam Pharmaceuticals is www.alnylam.com.

Where are Alnylam Pharmaceuticals' headquarters?

Alnylam Pharmaceuticals is headquartered at 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142.

How can I contact Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at [email protected], or via fax at 617-551-8101.


This page was last updated on 11/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.